FDA Approves Conversion of Soliris® (eculizumab) Accelerated Approval in aHUS to Regular Approval for the Treatment of Patients with aHUS

[Business Wire] – Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved the Company’s supplemental Biologics License Application providing regular approval for Soliris® for the treatment of adult and pedia more

View todays social media effects on ALXN

View the latest stocks trending across Twitter. Click to view dashboard

See who Alexion is hiring next, click here to view